Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors
In laboratory studies, SIL204 achieved an impressive ~90% inhibition rate in GP2D human colorectal cancer cells, with significant, dose-dependent reductions also observed in pancreatic (Panc-1) and lung (A427) cancer cell lines harboring the KRAS G12D mutation. This marks a major advance, as KRAS mutations are among the most common and challenging targets in oncology, driving roughly 90% of pancreatic, 45% of colorectal, and 35% of non-squamous NSCLC cases.
A hand holding cancer cells with a magnifying glass, highlighting the company's target of curing diseases.
SIL204's innovative lipid-conjugated delivery system enhances cellular uptake, enabling high efficacy at nanomolar concentrations and potentially overcoming resistance that limits conventional therapies.
The company plans further preclinical studies focusing on lung cancer cell lines to expand the evidence base. With a global market opportunity exceeding $30 billion for these cancer types, Silexion Therapeutics Corp (NASDAQ:SLXN)'s RNAi approach could reshape treatment options for patients with hard-to-treat, KRAS-driven tumors.
While we acknowledge the potential of SLXN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLXN and that has 100x upside potential, check out our report about this
READ NEXT: and
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Why monday.com (MNDY) Stock Is Trading Lower Today
What Happened? Shares of work management platform (NASDAQ:MNDY) fell 3.9% in the morning session after Bank of America downgraded the stock from "Buy" to "Neutral". The bank also lowered its price target on the stock to $205 from $240. The downgrade reflects growing concerns over the company's SEO-driven web traffic, which has reportedly seen a notable decline. According to the BofA Securities analyst, there is also potential for future revenue pressure on the company as search engines continue to integrate artificial intelligence. This shift in technology could impact how customers discover and interact with platform. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Access our full analysis report here, it's free. What Is The Market Telling Us shares are very volatile and have had 29 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 8 days ago when the stock gained 3.7% on the news that the SaaS sector continued to rally as favorable inflation data bolstered hopes for a Federal Reserve interest rate cut. This optimism was largely driven by a benign July Consumer Price Index (CPI) report, which solidified investor expectations for a Federal Reserve interest rate cut. Following the release of the inflation data, which showed a year-over-year increase of 2.7%, the probability of a rate cut in September surged to over 96%. Lower interest rates are typically beneficial for growth-oriented technology stocks, as they can reduce borrowing costs and increase the present value of future earnings. Adding to the positive sentiment was a 90-day delay in the imposition of higher tariffs on Chinese goods, which reduced trade-related uncertainty for the technology sector. is down 26% since the beginning of the year, and at $170.98 per share, it is trading 47.9% below its 52-week high of $327.92 from February 2025. Investors who bought $1,000 worth of shares at the IPO in June 2021 would now be looking at an investment worth $955.89. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Accuray (ARAY) Beats Q4 Revenue Estimates, BTIG Maintains Buy Rating
Accuray Incorporated (NASDAQ:ARAY) ranks among the . After Accuray Incorporated (NASDAQ:ARAY) reported fiscal fourth-quarter results and fiscal 2026 outlook, BTIG maintained its Buy rating on the radiation therapy company and increased its price target from $4 to $5 on August 14. Photo by Accuray on Unsplash Accuray's fiscal fourth-quarter revenue of $127.5 million exceeded consensus projections of $123.8 million, despite a 5% year-over-year decline. Product revenue of $70.7 million, which was over $4 million higher than the forecast, was the main driver of the sales beat, while services revenue of $56.8 million remained as expected. According to BTIG, Accuray Incorporated (NASDAQ:ARAY) overcame several obstacles during the quarter, such as the temporary suspension of shipments to China and the disruptions caused by Middle East hostilities in the EIMEA region. The firm thinks management has a realistic outlook for fiscal 2026, with room for improvement if macroeconomic headwinds and the tariff situation with China improve. Accuray Incorporated (NASDAQ:ARAY) that is involved in developing cutting-edge cancer and neuro-radiosurgery solutions. The CyberKnife technology, which treats primary and metastatic malignancies outside the brain, is the company's most well-known robotic stereotactic radiosurgery and stereotactic body radiation therapy technology. While we acknowledge the potential of ARAY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARAY and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
23 minutes ago
- Yahoo
Richtech Robotics (RR) Expands in China With $4 Million Sales Agreement
Richtech Robotics Inc. (NASDAQ:RR) ranks among the . Through its Chinese joint venture, Richtech Robotics Inc. (NASDAQ:RR) reported at the end of June that it had reached a sales agreement with Beijing Tongchuang Technology Development Co., Ltd. worth more than $4 million. possessed-photography-jIBMSMs4_kA-unsplash The contract covers the acquisition, maintenance, and software licensing of products from Richtech's ADAM, Scorpion, and Titan product lines. With analysts forecasting 33% rise in revenues for the fiscal year, the purchase is anticipated to boost the company's fourth-quarter revenue and create recurring revenue moving forward. According to a press release from the company, the new collaboration increases Richtech Robotics' footprint in China and could lead to new prospects throughout the Asian market. Richtech Robotics Inc. (NASDAQ:RR) specializes in interactive robotic solutions for the service sector, with additional applications in the healthcare and hotel industries. While we acknowledge the potential of RR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
